J Liver Cancer Search

CLOSE


J Liver Cancer > Epub ahead of print
DOI: https://doi.org/10.17998/jlc.2021.12.20    [Epub ahead of print]
Published online January 6, 2022.
A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases
Sang Yi Moon1  , Sang Young Han2  , Yang-Hyun Baek1 
1Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
2Department of Internal Medicine, On Hospital, Busan, Korea
Correspondence:  Yang-Hyun Baek, Tel: +82-51-240-2728, Fax: +82-51-240-2087, 
Email: p100100@dau.ac.kr
Received: 17 November 2021   • Revised: 8 December 2021   • Accepted: 12 December 2021
Abstract
Currently, various tyrosine kinase inhibitors and immune checkpoint inhibitors have been suggested in the treatment guidelines for advanced hepatocellular carcinoma (HCC). However, sorafenib was the only systemic drug approved 10 years ago. In 2010, a woman diagnosed with HCC rupture and multiple lung metastases visited our hospital. At the time of visiting our hospital, she had undergone transarterial chemoembolization at another hospital to control bleeding due to HCC rupture. We treated her with hepatic arterial infusion chemotherapy and sorafenib combination therapy to increase the control of intrahepatic tumors in consideration of the modest efficacy of sorafenib. The intrahepatic tumor was almost controlled. Metastasectomy was performed to control lung oligometastasis. Subsequently, additional muscle metastasis was confirmed, and metastasectomy was performed. Although this is a very rare case, it shows that a multidisciplinary approach can improve the prognosis of patients with HCC.
Key Words: Hepatocellular carcinoma; Intraarterial infusion; Metastasectomy; Case report


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR AUTHORS AND REVIEWERS
Editorial Office
1521 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2022 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next